Metabolomic Consequences of Genetic Inhibition of PCSK9 Compared with Statin Treatment

In this study, Nightingale’s blood biomarker analysis service was used to quantify 228 lipid and metabolite measures for 5,359 participants in the PROSPER trial at 6-months post-randomization and 72,185 individuals across eight population cohorts.